What is the role of oral and parenteral thrombin inhibitors and Xa inhibitors in the prevention of thrombosis?

Updated: Jan 05, 2018
  • Author: Paul Schick, MD; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print
Answer

Considerable efforts have recently been made to evaluate the role of oral and parenteral thrombin inhibitors and Xa inhibitors in preventing and managing thrombosis. The value of combining these agents with traditional warfarin and heparin therapy has been assessed. Disparate clinical settings such as patients with cancer, elderly patients, pregnancy, coronary artery disease, and surgical patients were studied. Although these studies have provided new information, many of them concluded that more information was needed to safely use new and standard anticoagulation therapy to provide optimal thrombosis prevention and management. these agents. [32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42]

Hospital formularies will be challenged to appropriately use and manage these new medications. [35] The introduction of new-generation anti-Xa and direct thrombin inhibitors in patients receiving antiplatelet therapy was associated with a dramatic increase in major bleeding events. [36]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!